Drug · DIN 02453177
IBRANCE
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since June 6, 2024; first marketed April 19, 2016.
- Drug Identification Number (DIN)
- 02453177
- Company (DIN owner)
- Pfizer Canada UlcKirkland, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Palbociclib L01EF01
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| PALBOCICLIB | 125 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 16, 2016: NOC 17885New Drug Submission (NDS)
Other DINs named IBRANCE
- DIN 02493535 · Marketed
- DIN 02493543 · Marketed
- DIN 02493551 · Marketed
- DIN 02453150 · Cancelled Post Market
- DIN 02453169 · Cancelled Post Market